Identification of the novel HLA-A*30:181 allele by next-generation sequencing.

HLA

Department of Oncohematology and Cell and Gene Therapy, Laboratory of Immunogenetics of Transplant, IRCCS Bambino Gesù Pediatric Hospital, Rome, Italy.

Published: February 2022

HLA-A*30:181 differs from HLA-A*30:01:01 by one nucleotide substitution in Exon 4832 G to A.

Download full-text PDF

Source
http://dx.doi.org/10.1111/tan.14450DOI Listing

Publication Analysis

Top Keywords

identification novel
4
novel hla-a*30181
4
hla-a*30181 allele
4
allele next-generation
4
next-generation sequencing
4
sequencing hla-a*30181
4
hla-a*30181 differs
4
differs hla-a*300101
4
hla-a*300101 nucleotide
4
nucleotide substitution
4

Similar Publications

Background: The prognosis for patients with several types of cancer has substantially improved following the introduction of immune checkpoint inhibitors, a novel type of immunotherapy. However, patients may experience symptoms both from the cancer itself and from the medication. A prototype of the eHealth tool Cancer Patients Better Life Experience (CAPABLE) was developed to facilitate symptom management, aimed at patients with melanoma and renal cell carcinoma treated with immunotherapy.

View Article and Find Full Text PDF

An external control arm based on health registry data can serve as an alternative comparator in single-arm drug development studies that lack a benchmark for comparison to the experimental treatment. However, accessing such observational healthcare data involves a lengthy and intricate application process, delaying drug approval studies and access to novel treatments. Clinical trials typically comprise only a few hundred patients usually with high-cardinality features, which makes individual data instances more exposed to re-identification attacks.

View Article and Find Full Text PDF

Reversed anatomy in transanal lateral lymph node dissection: landmarks and pitfalls.

Tech Coloproctol

January 2025

Department of Colorectal Surgery, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.

Lateral lymph node dissection (LLND) is getting global attention as an a surgical option to reduce local recurrence in locally advanced rectal cancer. As the transanal total mesorectal excision (TaTME) is gaining popularity worldwide, a novel LLND approach was established adopting a two-team approach that combines the transabdominal and transanal approaches using the TaTME technique. This narrative review describes the advantages, anatomical landmarks, surgical techniques, and pitfalls of transanal LLND (TaLLND).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!